CHAMPIONS ONCOLOGY, INC. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Champions Oncology reported Q1 FY2027 revenue of $15.2 million (up 8.8% from $14.0 million YoY), with oncology services margin improving to 51% from 43% prior year, driven by higher core research services conversion and increased data license revenue. Adjusted EBITDA increased to $671,000 from $59,000 YoY. Net loss narrowed to $426,000 from $466,000. Company ended quarter with $4.4 million cash, no debt, and 13.9 million shares outstanding.
Why this rating
Revenue growth 8.8% and margin expansion (51% vs 43%) with improving adjusted EBITDA ($671K vs $59K) show operational progress; however, company still unprofitable on GAAP basis. At $28.6M market cap, $15.2M quarterly revenue (~52% annualized) represents meaningful scale. Cash burn is modest (~$492K/quarter). Positive momentum but execution risk remains on sustainability and path to profitability.
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.